{
    "medicine_id": "e77b674ea413423f73f237314d85ae33f3051175",
    "platform_id": "DB09313",
    "metadata": {
        "name": "Hexabrix 39 3 g 100g Injection solution",
        "composition": "39 3 g 100g Ioxaglic acid",
        "clinical_particulars": {
            "therapeutic_indications": "This medicinal product is for diagnostic use only in adults and children as a low osmolality medium L1883 A7924",
            "contraindications": {
                "disease": "Adverse reactions after administration of iodinated contrast agents may be worsened in patients displaying agitation anxiety and pain Appropriate management such as sedation may be required before the procedure L1883 Adequate hydration and normal electrolyte balance must be ensured especially in elderly patients infants small children patients with renal damage oliguria polyuria or hyperuricemia multiple myeloma patients diagnosed with plasmacytoma or diabetes mellitus particularly if it is longstanding L1883 As this drug is a contrast agent it may cause minor or major reactions that may be serious or lethal L1883 They may be rapid within 60 minutes or delayed up to 1 week L1883 Emergency measures must be immediately available in high risk individuals especially in patients taking B blockers in whom adrenaline and vascular perfusion would not be effective L1883 There are several conditions in which caution must be observed while administering this contrast drug L1883 Renal Disease Hepatic Disease Particular attention is required if the patient has both hepatic and renal failure which increases the risk of contrast agent retention L1883 Cardiovascular Disease In patients with manifest or incipient heart failure coronary disease pulmonary hypertension or valvular heart disease the risks of pulmonary edema myocardial ischemia and arrhythmia and severe hemodynamic disturbances is heightened after the administration of an iodinated contrast agent Cases of Torsade de Pointes have been identified in patients using sodium and meglumine ioxaglate therefore loxaglic acid should be administered very carefully to patients who have may develop prolongation of QTc including patients taking other medicines that contribute to cardiovascular QT prolongation L1883 Pheochromocytoma Patients Patients with phaeochromocytoma may suddenly develop hypertension after intravascular administration of a contrast agent which may require appropriate management before the examination L1883 Thyroid Disease Following injection of iodinated contrast agent specifically in patients with goiter or a history of hypothyroidism there is a risk of either an episode of hyperthyroidism or induction of a new episode of hypothyroidism There is also a risk of hypothyroidism in newborns who have received or whose mother has received an iodinated contrast agent Screening for hypothyroidism should be performed routinely after administration of the product to newborns and judiciously to premature babies by assaying TSH and possibly free T4 7 10 days and 1 month after iodine overload L1883 Asthma Asthma should be controlled before injecting the iodinated contrast agent L1883 Particular attention is required if the asthmatic attack has occurred within eight days prior to administration of loxagic acid because of the increased risk for bronchospasm Myasthenia gravis Administration of a contrast agent may exacerbate the symptoms of myasthenia gravis L1883 Use in pregnancy In the patient screening and with appropriate tests it is advisable to identify possible pregnancy in women of childbearing age Exposure of the female genital tract to x rays warrants careful evaluation of the benefit to risk ratio L1883",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "This drug allows for the visualization of important organs and structures in the body It binds to tissues allowing the blockage of X rays and diagnostic visualization in various soft tissues and body cavities L1890 The joint spaces in addition to the uterus and fallopian tubes may be visualized by the direct injection of the contrast medium into the region to be studied L1885",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}